Building with passion and ingenuity.

TendoNova Corporation’s mission is to enhance clinical outcomes for patients with chronic tendon pain by delivering cutting edge microinvasive technology that is customizable to individual patient needs without overwhelming expense.



Mark A Samuels, CEO

Over 30 years of experience in Medical  Device, recent successful exit and prior IPO.  Inventor on over 25 patents.

Jason Wandersee, CFO

Executive and leader with specialty in corporate growth strategy and building high-performing teams. Previously served leadership roles as board member, CAO, COO, CEO.


Shaun Oveson, VP Sales and Marketing

Sales executive with a proven history of success and achievement in medical devices including 15 years of experience at Arthrex and Stryker prior.




Kenneth Mautner 



Gerard Malanga



Meagan Jennings



Rahul Desai


Dr. Mautner is the Assistant Professor in the Department of Physical Medicine and Rehabilitation and the Department of Orthopaedic Surgery at Emory University. He is also the Director of Primary Care Sports Medicine and Fellowship Director at Primary Care Sports Medicine Fellowship. Dr. Mautner is a co-editor of the Atlas of Interventional Musculoskeletal Ultrasound and Musculoskeletal Physical Examination: An Evidence Based Physical Approach. Dr. Mautner is considered a leader in the field of orthobiologics treatment for chronic soft tissue and joint disorders including Platelet Rich Plasma (PRP) and stem cell injections.

Dr. Malanga is the Founder and Partner of New Jersey Sports Medicine, LLC and New Jersey Regenerative Institute in Cedar Knolls, New Jersey. He is board certified in physical medicine and rehabilitation, sports medicine and pain medication. Dr. Malanga is trained in nonoperative treatment of a variety of orthopedic disorders including neck and back pain, as well as shoulder, knee, and other sports medicine and musculoskeletal problems. Dr. Malanga’s expertise includes EMG testing, spinal and joint injections, musculoskeletal ultrasound and PRP, bone marrow and adipose-derived stem cell treatments.

Dr. Jennings is the Director of Silicon Valley Foot & Ankle Reconstructive Fellowship at Palo Alto Medical Foundation. She is a board-certified foot and ankle surgeon with a focus on trauma, reconstruction, and sports medicine at Palo Alto Medical Foundation. Dr. Jennings’s expertise includes Achilles tendon, biomechanics, bunions, diabetic limb salvage, endoscopic plantar fascia surgery, foot surgery, heel surgery, and sports medicine.

Dr. Desai is the founder of RestorePDX, specializing in musculoskeletal radiology and interventional joint and spine medicine. He currently sits on the Board of Directors for the Interventional Orthopedics Foundation. Dr. Desai has expanded his musculoskeletal imaging background (MSK ultrasound, diagnostic MRI, CT, X-ray, interventional fluoroscopy) in combination with PRP, stem cells, and regenerative medicine.



Lou Malice

Lou Malice

Peter Haaland

Medical Device Executive with 30+ years of experience in commercialization, R&D, manufacturing, supply chain, and regulatory. Veteran of start-up & growth stage medical device companies​.

Medical Device Executive with 30+ years of experience in commercialization, R&D, manufacturing, supply chain, and regulatory. Veteran of start-up & growth stage medical device companies​.


  • LinkedIn - Grey Circle

Brett Rogers

  • LinkedIn - Grey Circle


Shawna Khouri

Luka Grujic
  • LinkedIn - Grey Circle


Luka Grujic

Jonathan Shaw
  • LinkedIn - Grey Circle


Jonathan Shaw




Tendinopathy is an injury that has failed to heal and is one of the most common causes of pain in the world.

  • 30 million Americans have chronic tendon pain (lasting over 3 months).
  • Five commonly affected tendon areas include: jumper’s knee, tennis elbow, golf elbow, plantar fasciitis, Achilles tendinopathy, and other tendons.
  • 9 million Americans fail to respond to conservative treatment.
  • Approximately $1.4 billion of the market is currently unmet.


(Suboptimal for symptom reduction)

  • Conservative Treatment

  • Percutaneous Tenotomy

  • Open Surgery





TendoNova’s Ocelot System is a microinvasive technology designed to perform percutaneous tenotomy under ultrasound-guided procedures

  • TendoNova’s Ocelot System is inserted transdermally under ultrasound guidance and used to mechanically debride, separate, puncture, and dissect soft tissue.

  • The controlled physical disruption of the pathologic tendon allows the healing cycle to restart and create healthy tendon remodeling. The purpose of this effect is to treat chronic tendon injuries that lead to pain and disability in multiple populations.

  • The Ocelot System provides first real-time objective measurement of procedure effect and allows for data-gathering for long term improvements.

  • The system is a wireless, battery powered, portable, handheld device that consists of a reusable drive unit, disposable tool components, and a charging station.


Improved Clinical Outcomes

  • Through standardized objective measurements we improve both novice and expert clinician’s outcomes

Decreased Cost of Care

  • Less expensive and invasive than alternative procedures that need to be done in the OR or Ambulatory Surgical Suite

Improved Patient Experience

  • Reduced time and cost: only requires an office visit vs. ASC

  • Increased comfort: more precise than existing tools

  • Requires less movement in the body

Improved Physician Experience

  • Wireless, with little set up time

  • Objective measurements on which to base and defend clinical decisions

  • Economical without sacrificing results


Find a Doctor

TendoNova can help you
find an Ocelot System Doctor!

Fill out a request here:

Coming Soon. Stay tuned for updates.



Thank you for your interest in TendoNova Corporation.
Our corporate office’s address and information are listed below:


TendoNova Corporation

3050 Business Park Dr. •  Suite A-2 • Norcross, GA 30071
E: info@tendonova.com 



Please email mark.samuels@tendonova.com
regarding investor inquiries.